PUBLISHER: IMARC | PRODUCT CODE: 1702206
PUBLISHER: IMARC | PRODUCT CODE: 1702206
The global protein expression market size reached USD 3.1 Billion in 2024. Looking forward, IMARC Group expects the market to reach USD 6.6 Billion by 2033, exhibiting a growth rate (CAGR) of 8.56% during 2025-2033.
Protein expression refers to a biotechnological process, wherein proteins are modified, synthesized and regulated in living organisms. Transcription, translation and post-translational modifications are some of the processes involved in protein expression. It includes various expression systems that are generally derived from bacterial, algal, insect, cell-free, yeast and mammalian cells. Protein expression is widely used to study the presence of one or more proteins in the tissues or cells. It offers several advantages, such as high expression, good stability, fast-breeding, strong anti-pollution ability and easy purification of the product. As a result, it is commonly used by biotechnologists, pharmaceutical companies, contract research organizations (CROs) and academic research institutes for proteomics.
The increasing demand for therapeutic proteins, such as vaccines, peptide hormones, therapeutic enzymes, cytokines, antibodies, and blood factors, on account of rising prevalence of chronic diseases, especially amongst the geriatric population is creating a positive outlook for the market. In line with this, the widespread product utilization in the manufacturing of biologics as they play an important role in the treatment process of various health issues is favoring the market growth. Apart from this, various advancements and innovations in mass spectrometry and molecular genetics that assist in accurate mass determination and characterization of proteins, are providing an impetus to the market growth. Additionally, the rising demand for cell-free protein expression due to its ability to express toxic proteins, increase speed and enhanced overall yields of functional, soluble, full-length proteins is positively impacting the market growth. Other factors, including extensive research and development (R&D) activities and increasing product demand from pharmaceutical and biotechnology companies, are anticipated to drive the market toward growth.
The competitive landscape of the industry has also been examined along with the profiles of the key players being Agilent Technologies Inc., Becton Dickinson and Company, Bioneer Corporation, Bio-Rad Laboratories Inc., Lonza Group AG, Merck KGaA, New England Biolabs, Promega Corporation, Qiagen N.V., Sino Biological Inc., Takara Bio Inc. and Thermo Fisher Scientific Inc.